Merck & Co’s CEO Ken Frazier has received the strongest possible backing from the company’s board, after it was announced the pharma company has rescinded a mandatory retirement age pol
Roche is eyeing a new use for its checkpoint inhibitor immunotherapy Tecentriq after it posted results showing it extended patients’ lives by an extra two months compared with chemotherapy
The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was previously only treatable with chemotherapy.
Australian biotech Immutep has begun a clinical trial partnership with Germany’s Merck KGaA and Pfizer to develop a new cancer immunotherapy combination therapy.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
